Skip to search formSkip to main contentSkip to account menu

panobinostat

Known as: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)- 
A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Histone deacetylases (HDACs) catalyze the cleavage of acetyl groups from N-acetyl-lysine residues of histones and non-histone… 
2014
2014
Recently, treatment with bromodomain and extraterminal protein antagonist (BA) such as JQ1 has been shown to inhibit growth and… 
2010
2010
1115 Background: In vivo experiments have demonstrated synergy when the histone deacetylase (HDAC) inhibitors are combined with… 
2010
2010
8007 Background: Panobinostat (PAN) is a pan-deacetylase inhibitor targeting epigenetic and non-epigenetic oncogenic pathways. In… 
2010
2010
TPS283 Background: Medical treatment options for myelofibrosis (MF) are palliative in nature. Short of allogeneic stem cell… 
2010
2010
e17521 Background: Panobinostat (P) is a pan deacetylase inhibitor hydroxamic acid derivative, currently in the clinic in several… 
2010
2010
TPS308 Background: BTZ, a backbone of novel therapy for patients (pts) with MM, is an effective agent but pts will relapse and… 
2010
2010
e13089 Background: Panobinostat (PAN; LBH589) has been found to inhibit CYP2D6 in vitro. It was hypothesized that PAN may inhibit… 
2009
2009
Panobinostat is a novel cinnamic hydroxamic acid pan-deacetylase inhibitor able to induce hyperacetylation of lysine residues on…